Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Eli Lilly · Phase 2 · Completed · Enrollment 354

NCT06326060

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Dosing scheme a: NNC0519-0130n/rn/rn/rn/r
Dosing scheme a: Placebon/rn/rn/rn/r
Dosing scheme b: NNC0519-0130n/rn/rn/rn/r
Dosing scheme b: Placebon/rn/rn/rn/r
Dosing scheme c: NNC0519-0130n/rn/rn/rn/r
Dosing scheme c: Placebon/rn/rn/rn/r
Dosing scheme d: NNC0519-0130n/rn/rn/rn/r
Dosing scheme d: Placebon/rn/rn/rn/r
Dosing scheme e: NNC0519-0130n/rn/rn/rn/r
Dosing scheme e: Placebon/rn/rn/rn/r
Dosing scheme f: NNC0519-0130n/rn/rn/rn/r
Dosing scheme f: Placebon/rn/rn/rn/r
Dosing scheme g: Tirzepatiden/rn/rn/rn/r

Not shown

  • Dosing scheme a: NNC0519-0130: endpoint not reported
  • Dosing scheme a: Placebo: endpoint not reported
  • Dosing scheme b: NNC0519-0130: endpoint not reported
  • Dosing scheme b: Placebo: endpoint not reported
  • Dosing scheme c: NNC0519-0130: endpoint not reported
  • Dosing scheme c: Placebo: endpoint not reported
  • Dosing scheme d: NNC0519-0130: endpoint not reported
  • Dosing scheme d: Placebo: endpoint not reported
  • Dosing scheme e: NNC0519-0130: endpoint not reported
  • Dosing scheme e: Placebo: endpoint not reported
  • Dosing scheme f: NNC0519-0130: endpoint not reported
  • Dosing scheme f: Placebo: endpoint not reported
  • Dosing scheme g: Tirzepatide: endpoint not reported